hVIVO plc 2017 Annual Report and Financial Statements (4306M)

TIDMHVO

RNS Number : 4306M

hVIVO plc

27 April 2018

For immediate release 2.00pm: 27 April 2018

HVIVO PLC

("hVIVO" or the "Company")

2017 Annual Report and Financial Statements

hVIVO plc (AIM: HVO), a pioneer of human disease models and an industry leading clinical development and drug discovery services business, is pleased to announce that its Annual Report and Financial Statements for the year ended 31 December 2017 is being posted to shareholders today.

It will be available on the Company's website (http://hvivo.com/investors/financial-reports/) from 4.30 pm today.

For further information please contact:

 
 hVIVO plc 
 Trevor Phillips (Executive 
  Chairman)                        +44 207 756 1300 
 Fleur Wood (Director, Investor 
  Relations) 
 Numis Securities Limited           +44 207 260 1000 
 Michael Meade / Freddie 
  Barnfield (Nominated Adviser) 
 James Black / Michael Burke 
  (Corporate Broking) 
 
 FTI Consulting 
 Simon Conway / Victoria 
  Foster Mitchell                  +44 203 727 1000

Notes to Editors:

hVIVO plc ("hVIVO") is pioneering a human-based analytical platform to accelerate drug discovery and development in respiratory and infectious diseases. Leveraging human disease models in flu, RSV and asthma exacerbation, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted more than 50 clinical studies, inoculated over 2500 volunteers and has three first-in-class therapies currently in development with a growing pre-clinical pipeline.

This information is provided by RNS

The company news service from the London Stock Exchange

END

ACSFKODQBBKDAQB

(END) Dow Jones Newswires

April 27, 2018 09:00 ET (13:00 GMT)

Hvivo (LSE:HVO)
Historical Stock Chart
From Apr 2024 to May 2024